Call Options

9 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2023

Aug 11, 2023

SELL
$1.08 - $1.65 $115,344 - $176,220
-106,800 Reduced 72.11%
41,300 $49,000
Q1 2023

May 16, 2023

SELL
$0.78 - $1.42 $19,734 - $35,926
-25,300 Reduced 14.59%
148,100 $173,000
Q4 2022

Feb 14, 2023

BUY
$0.79 - $1.28 $17,380 - $28,160
22,000 Added 14.53%
173,400 $136,000
Q3 2022

Nov 14, 2022

BUY
$0.14 - $1.33 $1,652 - $15,694
11,800 Added 8.45%
151,400 $183,000
Q2 2022

Aug 15, 2022

SELL
$0.88 - $1.87 $45,584 - $96,866
-51,800 Reduced 27.06%
139,600 $128,000
Q1 2022

May 16, 2022

SELL
$1.38 - $1.89 $265,926 - $364,203
-192,700 Reduced 50.17%
191,400 $343,000
Q4 2021

Feb 14, 2022

SELL
$1.51 - $2.2 $257,455 - $375,100
-170,500 Reduced 30.74%
384,100 $592,000
Q3 2021

Nov 15, 2021

BUY
$1.74 - $2.6 $826,326 - $1.23 Million
474,900 Added 595.86%
554,600 $1.13 Million
Q2 2021

Aug 11, 2021

BUY
$1.51 - $4.23 $120,347 - $337,131
79,700 New
79,700 $277,000

Others Institutions Holding CTXR

About Citius Pharmaceuticals, Inc.


  • Ticker CTXR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 146,130,000
  • Market Cap $65.8M
  • Description
  • Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic l...
More about CTXR
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.